Targeted Immunotherapies MAIA Biotechnology focuses on first-in-class targeted immunotherapies for cancer with potential activity across multiple tumor types, presenting opportunities for collaboration with oncology developers, contract research organizations, and specialty pharma seeking novel mechanisms.

Phase 3 Pipeline The company is advancing a pivotal Phase 3 trial (THIO-104) and has demonstrated ongoing conference activity, signaling near-term clinical milestones that could attract potential partners, licensing discussions, or co-development arrangements.

Diversified Subsidiaries MAIA operates drug candidates in dedicated subsidiary entities under a lean, capital-efficient structure, which may facilitate structured partnership opportunities, asset-level licensing, or deal terms tailored to individual programs.

Capital Reach Publicly traded status with notable clinical-stage activity and selective financing events indicate ongoing capital needs and investor interest; this could align with strategic collaborations, milestone-based partnerships, or financing conversations to support late-stage development.

Industry Engagement Frequent attendance and presentations at major conferences (ASCO, AACR-NCI-EORTC, IASLC, ESMO, BIO) provide natural channels for sales teams to engage researchers, identify collaboration or licensing interests, and accelerate visibility for MAIA assets among oncology KOLs.